Patients with frailty, benign prostatic hyperplasia and indwelling bladder catheter: What are the 1-year outcomes after Rezūm therapy? [0.03%]
Rezūm疗法治疗虚弱、良性前列腺增生和留置膀胱导管患者的1年随访结果如何？
Raffaele Balsamo,Simone Tammaro,Ferdinando Fusco et al.
Raffaele Balsamo et al.
Background: Rezūm therapy, a minimally invasive surgical procedure for benign prostatic hyperplasia (BPH), was very recently developed. Its characteristics and safety profile render its use in patients with multiple como...
Tackling the progression of benign prostatic hyperplasia/benign prostatic obstruction progression: Deobstructing within the "window of curability" (a hypothesis-generating review) [0.03%]
前列腺增生/梗阻进程的防治：“可治愈窗口期”内的去梗阻治疗（一篇启发思考的综述）
Wayne W Kuang,Luca Cindolo,Tareq Alsaody et al.
Wayne W Kuang et al.
Benign prostatic hyperplasia (BPH) and benign prostatic obstruction (BPO) remain significant contributors to male lower urinary tract symptoms, often leading to bladder damage and dysfunction. The traditional approach focuses on the managem...
Does the dorsal plication matter with the results of primary hypospadias repair? [0.03%]
背侧成型术对原发性阴茎尿道下裂修补结果有影响吗？
Xuemin Wu,Guoqiang Du,Hongwei Wang et al.
Xuemin Wu et al.
Background: In this study, we aimed to evaluate the efficacy of dorsal plication (DP) in correcting mild-to-moderate ventral penile curvature (VPC) during primary hypospadias repair with urethral plate preservation. ...
Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study [0.03%]
联合程序性死亡蛋白1抑制剂和多聚(腺苷二磷酸-核糖)聚合酶抑制剂治疗转移性去势抵抗性前列腺癌患者：真实世界研究的启示
Yuan Shao,Zihao Liu,Yinchi Zhang et al.
Yuan Shao et al.
Background: This study aimed to evaluate the clinical efficacy and safety of combining a programmed cell death protein 1 (PD-1) inhibitor with a poly(ADP-ribose) polymerase inhibitor (PARPi) in patients with metastatic ca...
Identification of KRBA2 as a probable prognostic biomarker correlated with immune infiltration in kidney clear cell carcinoma [0.03%]
识别出的KRBA2可能是与肾脏透明细胞癌免疫浸润相关的预后生物标志物
Kai Sun,Qingliang Wang,Yanning Sun et al.
Kai Sun et al.
Background: Kidney renal clear cell carcinoma (KIRC) is a major subtype of renal cell carcinoma. Because of its rapid progression and resistance to targeted therapies, KIRC poses a significant threat to human health. KRBA...
Chimeric antigen receptor-based cell therapy for treating urological tumors [0.03%]
基于嵌合抗原受体的细胞治疗在泌尿系统肿瘤中的应用
Huidi Tang,Linpei Guo,Wen Zhang et al.
Huidi Tang et al.
Urological tumors represent a significant global health challenge, with conventional therapies often proving insufficient to control disease progression. Recent breakthroughs in cellular immunotherapy, particularly in chimeric antigen recep...
The interconnection between androgen receptor and DNA damage response pathways in prostate cancer [0.03%]
前列腺癌中雄激素受体与DNA损伤反应通路的相互作用
Mallory Sands,Samuel Adams,Jihaeng Lee et al.
Mallory Sands et al.
The androgen receptor (AR) plays a critical role in the development and progression of prostate cancer by regulating key cellular processes such as cell proliferation and apoptosis. Although traditional AR-targeted therapies have shown init...
The GreenLight laser, an example of flexibility: Lessons learned from the Italian GreenLight Study Group [0.03%]
意大利GreenLight研究小组的启示：GreenLight激光手术的灵活性
Mattia Sibona,Paolo Destefanis,Paolo Gontero
Mattia Sibona
A case series and literature review of renal anastomosing hemangioma: An often-misdiagnosed benign tumor [0.03%]
肾并指状血管瘤的病例系列及文献回顾：一种常被误诊的良性肿瘤
Jialong Song,Cheng Peng,Xiaohui Ding et al.
Jialong Song et al.
Background: Renal anastomosing hemangiomas (RAHs) are rare. This study aimed to summarize the clinical, pathological, and imaging characteristics of RAH. ...
Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021 [0.03%]
2010年至2021年接受根治性前列腺切除术的G1期前列腺癌升级和分期变化趋势：NCDB与SEER结果分析
Evan Suzman,Shu Wang,Jim C Hu
Evan Suzman